Dermatology
Erythema Multiforme
6
Pipeline Programs↗
1
Active Trials↗
4
Companies Involved↗
Erythema Multiforme is an early-stage landscape with 6 programs across 4 companies. The most active players are Amgen, Pfizer, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 2 therapies are approved with 2 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Analysis
Trial Status
2
clinical trials
Not yet recruiting1 · 50%
Completed1 · 50%
Clinical Trials
Trial Activity
Apremilast for Erythema Multiforme
Completed·—·Phase 2·NCT05875714·8 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)